Clinical Trial

Phase 2 Study Assessing the Clinical Activity and Safety of Obecabtagene Autoleucel as a Consolidation in Patients With Newly Diagnosed High-risk B-cell Acute Lymphocytic Leukemia (ALL)

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The goal of this clinical research study is to learn if obecabtagene autoleucel (obe-cel) can help to control newly diagnosed, high-risk B-cell ALL when given as consolidation therapy. Consolidation therapy is given after the first phase of treatment.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-06-30; most recent amendment 2026-04-29.
Status change: Not Yet Recruiting → Recruiting 2025-08-28
Trial Details
NCT Number NCT07053059
Lead Sponsor M.D. Anderson Cancer Center
Collaborators: Autolus, Ltd
Conditions Acute Lymphocytic Leukemia (ALL)
Enrollment 30 participants
Start Date 2025-08-26
Primary Completion 2028-05-31 (estimated)
Study Completion 2030-05-31 (estimated)
Updated on ClinicalTrials.gov 2026-08-12